SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Akkerman Onno W.)
 

Sökning: WFRF:(Akkerman Onno W.) > Derivation and Clin...

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment

Keutzer, Lina (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Mockeliunas, Laurynas (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Sturkenboom, Marieke G. G. (författare)
Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, NL-9713 GZ Groningen, Netherlands.
visa fler...
Bolhuis, Mathieu S. (författare)
Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, NL-9713 GZ Groningen, Netherlands.
Akkerman, Onno W. (författare)
Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis & TB, NL-9713 GZ Groningen, Netherlands.;Univ Groningen, Univ Med Ctr Groningen, TB Ctr Beatrixoord, NL-9751 ND Groningen, Netherlands.
Simonsson, Ulrika S. H., Professor (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
visa färre...
 (creator_code:org_t)
MDPI, 2023
2023
Engelska.
Ingår i: Pharmaceuticals. - : MDPI. - 1424-8247. ; 16:11
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75 drug-resistant tuberculosis patients treated with linezolid were analyzed using a time-to-event (TTE) approach for peripheral neuropathy and anemia and indirect response modelling for thrombocytopenia. Different time-varying linezolid pharmacokinetic exposure indices (AUC0-24h,ss, Cav, Cmax and Cmin) and patient characteristics were investigated as risk factors. A treatment duration shorter than 3 months was considered dropout and was modelled using a TTE approach. An exposure-response relationship between linezolid Cmin and both peripheral neuropathy and anemia was found. The exposure index which best described the development of thrombocytopenia was AUC0-24h. The final TTE dropout model indicated an association between linezolid Cmin and dropout. New safety targets for each adverse event were proposed which can be used for individualized linezolid dosing. According to the model predictions at 6 months of treatment, a Cmin of 0.11 mg/L and 1.4 mg/L should not be exceeded to keep the cumulative probability to develop anemia and peripheral neuropathy below 20%. The AUC0-24h should be below 111 h center dot mg/L or 270 h center dot mg/L to prevent thrombocytopenia and severe thrombocytopenia, respectively. A clinical utility assessment showed that the currently recommended dose of 600 mg once daily is safer compared to a 300 mg BID dosing strategy considering all four safety endpoints.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

tuberculosis
pharmacokinetics
linezolid
Monte Carlo simulation
indirect response modelling
time-to-event analysis
safety
peripheral neuropathy
myelosuppression
clinical utility index

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy